Brain

IRLAB to present at Pareto Securities’ Healthcare Conference in Stockholm on September 14, 2023

GOTHENBURG, SWEDEN / ACCESSWIRE / September 13, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 13, 2023 - IRLAB Therapeutics…

10 months ago

Hemostemix Announces New Publication: How NCP-01 Supports Brain Computer Interfaces

Calgary, Alberta--(Newsfile Corp. - September 12, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce…

10 months ago

Nordic Naturals Expands Retail Presence with Exclusive Omega-3 Supplement Offerings Coming to Sam’s Club Stores in October

Nordic Naturals Ultimate Omega at Sam's Club Nordic Naturals’ Ultimate Omega 100 count omega-3 supplements will be available exclusively in…

10 months ago

Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV

PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary…

10 months ago

NeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves Quality of Life of Adolescents with IBS

CARMEL, Ind., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology…

10 months ago

Baylor Genetics Announces Neurodevelopmental Disorders Test Panel to Help Healthcare Providers Diagnose Patients with Intellectual Disabilities or Developmental Delays

New Test Analyzes Highly Curated Set of 236 Genes Most Associated with Autism Spectrum Disorder, Intellectual Disabilities, and Developmental Delay.HOUSTON,…

10 months ago

Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease

Treatment Could Help Restore Brain Functions Lost in Many Neurogenerative DisordersSAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc.,…

10 months ago

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as…

10 months ago

Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting

SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical…

10 months ago